Research Report on China Human Vaccine Industry 2016-2020 - MSD, Sanofi, Glaxo SmithKline, Pfizer and Novartis Dominate with 80% Market Share -- Research and Markets
DUBLIN, July 4, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Research Report on China Human Vaccine Industry, 2011-2020" report to their offering.
In 2015, vaccine market size in China had a value of about CNY 21 billion. During the corresponding period, however, the whole pharmaceutical market in China reached a scale of over CNY 2,000 billion.
Five pharmaceutical giants, MSD, Sanofi, Glaxo SmithKline, Pfizer and Novartis, take up significant share of the global market, with sales volume of over 80% globally.
Currently vaccination is one of the most effective approaches to prevent the spread of infectious diseases as well as one of the most cost-effective health intervention measures. Vaccination is helpful to trim down large amount of treatment expense.
The research object of the report is human vaccine apart from animal vaccine. Five pharmaceutical giants, MSD, Sanofi, Glaxo SmithKline, Pfizer and Novartis, take up significant share of the global market, with sales volume of over 80% globally. Yet in terms of vaccine output, these five giants totally produce less than 20% of the global output, meaning most of the vaccines are produced by manufacturers in the developing world.
There are more than 30 vaccine manufacturing companies in China so far. They are capable of producing over 40 varieties of vaccines to prevent more than 20 infectious diseases. Compared with the international market, vaccine manufacturing companies in China have a larger total number yet a smaller individual scale.
Vaccine I refers to those free vaccines provided by the government for the public, including vaccines against major epidemic diseases such as hepatitis B, epidemic meningitis and tetanus. Vaccines in this category are all priced by the government and purchased through bidding. Vaccine II mainly covers vaccines paid by citizens themselves.
For Vaccine II, pricing falls into the hand of companies, thus offering a higher profit margin and yet forming a more fiercely competitive market. Some of the commonly used vaccines in the Vaccine II catalogue include Pneumonia Vaccine, Varicella Vaccine, Type B Haemophilus Influenzae Conjugate Vaccine, Influenza Vaccine and Rabies Vaccine. In China, Vaccine I market is dominated by state-owned enterprises. Foreign and private enterprises gain certain advantages in the Vaccine II market.
Key Topics Covered:
1 Basic Concept of Human Vaccine
2 Analysis on the Global Human Vaccine Market, 2011-2015 2.1 Scale and Structure of Global Vaccine Market 2.2 Vaccines for Children 2.3 Adult Vaccines
3 Development Environment of China Human Vaccine Industry, 2011-2016
3.1 Economic Environment
3.2 Policy Environment
3.3 Relevant Legislation and Criterion of China Vaccine Industry
3.4 Analysis on Problems in China Human Vaccine Industry
4 Analysis on the China Human Vaccine Market, 2011-2015 4.1 Classification of Chinese Vaccines 4.2 Scale of China Vaccine Market 4.3 Classification of Chinese Vaccines According to Government Regulation Degrees 4.4 Market Analysis on Major Vaccines in China
5 China's Major Vaccine Manufacturers, 2011-2015
5.1 China National Biotec Group
5.2 Hualan Biological Engineering Co., Ltd.
5.3 Yunnan Walvax Biotechnology Co., Ltd.
5.4 Dalian Hissen Biological Pharmaceutical Co., Ltd.
5.5 Changchun High-Tech Industry Co., Ltd.
5.6 Shenzhen Kangtai Biological Products Co., Ltd.
5.7 Neptunus Interlong Bio-Technique Co., Ltd.
5.8 Liaoning Chengda Biotechnology Co., Ltd.
5.9 ChongQing ZhiFei Biological Products Co., Ltd.
6 Prospect of China Vaccine Industry, 2016-2020 6.1 Prediction on Supply and Demand 6.2 Prediction on Development Trend
For more information visit http://www.researchandmarkets.com/research/nhbf5s/research_report
Media Contact:
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Share this article